Recently, assist cancer detection company Vigilant Biosciences announced that it got another 5 million dollars of B round financing, invested by White Owl Capital Partners and venVelo.

Recently，US seed company Monsanto refused Germany Bayer’s takeover bid that up to 65 billion dollars. But at the same time, it also said it would keep an open attitude to negotiate with Bayer and other bidders.

Recently，Bio-Techne announced that it has agreed to acquire Advanced Cell Diagnostics for $250 million in cash, plus an additional consideration of $75 million if certain milestones are achieved.

Recently, the medical equipment company NVision Medical announced the accomplishment of its B round financing, which has raised 12 million USD,leading by Arboretum Ventures, and followed by Catalyst Health Ventures.

Under the present medical system, the influence of human genome is very limited, because of some basic challenges: the providers cannot receive the related resources in time,

Recently, NEEQ (National Equities Exchange and Quotations) notice shows that Hefei Sunshine Medical Technology Co., Ltd was approved to list on the new OTC market and public transfer.

AUG 18, NEEQ (National Equities Exchange and Quotations) notice shows that Fapon Biotech Inc. was approved to list on the new OTC market and public transfer.

According to information in the industry, recently, based-in Zhang Jiang gene detection company Singlera Genomics had received A round funding of 20 million dollars.

Recently, Sydney-based biological diagnostic technology company Atomo Diagnostics had completed a round of finance, of which the total number was 3.5 million dollars.

Recently, Beijing Jabrehoo medical technology co., LTD. had held a signing ceremony with the United States Illumina in Beijing. The partners had made the strategic cooperation on jointly developing and promoting the assisted reproduction diagnosis methods

Nanosphere announced today that it has completed a $10 million public offering. The Northbrook, Illinois-based molecular diagnostics firm priced the offering at $.47 per share. Each share was coupled with a fi..

Over the past seven years, Celgene has emerged as one of the most active and creative deal-makers in the biopharma industry. Using my descriptors, not their’s (in case they don’t like them), here are t..

The oncolytic immunotherapy of Amgen yields unusually brilliant results this year. After it was approved by FDA in October, Imlygic was approved again in Europe last week. Now it becomes the first oncolytic immunother..

In December 21, 2015, genomics service provider GENEWIZ announced that it has signed a definitive agreement to acquire the U.S. company Beckman's genome business, the business includes global genome business, heal..

Switzerland's CRISPR Therapeutics and Germany's Bayer today announced a yet unnamed joint venture to develop ways to deliver CRISPR/Cas9 genome editing in a clinical setting. The deal brings together Baye..